StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a report issued on Friday. The brokerage set a "hold" rating on the stock.
Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of DBV Technologies in a report on Thursday, August 1st. JMP Securities restated a "market outperform" rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Tuesday.
Get Our Latest Stock Report on DBV Technologies
DBV Technologies Price Performance
DBV Technologies stock traded up $0.03 during midday trading on Friday, hitting $0.71. 37,813 shares of the stock were exchanged, compared to its average volume of 51,896. DBV Technologies has a 1 year low of $0.50 and a 1 year high of $2.74. The firm has a market cap of $68.62 million, a P/E ratio of -0.82 and a beta of 0.68. The company has a 50 day moving average price of $0.87 and a two-hundred day moving average price of $1.08.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same quarter in the prior year, the company posted ($0.26) EPS. As a group, analysts predict that DBV Technologies will post -1.43 EPS for the current year.
Hedge Funds Weigh In On DBV Technologies
A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company's stock after purchasing an additional 327,345 shares during the period. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.'s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 71.74% of the company's stock.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
